While GSK is still emerging from a phase of slow growth, the US market is showing an increasing pricing pressure. The next wave of drug launches from an active pipeline of 25 clinical programmes will determine how strongly GSK charts its future growth. One dollar in every four that GSK sells worldwide comes from a new product which is less than three years old,” said Witty. “The choice I made is that we can either have a challenge, and do a big merger to fix it, or don’t do a big merger to force yourself to organically change. On the UK-India business delegation that accompanied May, Witty said the UK and India can collaborate more on regulatory harmonisation.

Source: Economic Times November 08, 2016 19:36 UTC